FDA gets new power to fast-track drugs from prescription to over-the-counter
S. 2292 — Over-the-Counter Monograph Drug User Fee Amendments · Filed by Jim Banks (R-IN) · 3 cosponsors · Introduced Jul 15, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes and modifies the FDA's user-fee program for over-the-counter (OTC) monograph drugs—common remedies like antacids and cough syrups that don't require individual drug approval. The bill extends the fee program through 2030, adjusts how much manufacturers must pay based on inflation and workload, and adds new FDA reporting requirements on drug safety and supply-chain stability. It also creates a clearer pathway for prescription drugs to be switched to OTC status and directs the FDA to consider alternatives to animal testing for topical drugs like sunscreens.
Why we flagged it
The bill's core function is reauthorizing an existing FDA fee program for OTC drugs through 2030, with amendments to fee structure, reporting, and regulatory standards. The Rx-to-OTC and animal-testing provisions are substantive modernizations, not riders.
What the text implies
- Voluntary consensus standards for topical-drug testing (Section 6) may allow manufacturers to avoid more rigorous FDA-mandated testing if industry standards are weaker, potentially reducing safety oversight for sunscreens and other topical OTC drugs.
- Fee increases (base revenue plus inflation adjustments) will likely be passed to consumers through higher OTC drug prices, disproportionately affecting lower-income households that rely on affordable OTC remedies.
The full analysis lists 5 implications of this text.
Who stands to gain
OTC drug manufacturers (reduced regulatory burden via voluntary standards and streamlined Rx-to-OTC; Contract manufacturing organizations (registration and fee collection framework); Pharmaceutical companies seeking Rx-to-OTC switches (clearer approval pathway, reduced animal testin